{{위키데이터 속성 추적}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 470472739
| IUPAC_name = (2''S'',5''R'')-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
| image = Sulbactam.svg
| width = 150
| image2 = Sulbactam ball-and-stick.png
| width2 = 200
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|sulbactam}}
| MedlinePlus = a693021
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration = [[정맥 주사]], [[근육 주사]]
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 29%
| metabolism =
| elimination_half-life = 0.65~1.20시간
| excretion = 주로 [[콩팥]] (8시간 내에 41~66%)
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 68373-14-8
| ATC_prefix = J01
| ATC_suffix = CG01
| PubChem = 130313
| DrugBank_Ref = 
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 115306
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S4TF6I2330
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08533
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9321
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 403
<!--Chemical data-->
| C=8 | H=11 | N=1 | O=5 | S=1
| smiles = O=S2(=O)C([C@@H](N1C(=O)C[C@H]12)C(=O)O)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FKENQMMABCRJMK-RITPCOANSA-N
| melting_point = 148
| melting_high = 151
}}
<!-- Definition and medical uses -->
'''설박탐'''(sulbactam)은 [[베타-락타메이스 억제제]]의 일종이다. [[베타-락탐 계열 항생제]]와 병용하며, 이 항생제를 파괴하는 [[세균]]의 [[효소]]인 [[베타-락타메이스]]를 억제한다.<ref name="pmid17630699">{{저널 인용| vauthors = Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR | title = Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase | journal = Biochemistry | volume = 46 | issue = 31 | pages = 8980–8987 | date = August 2007 | pmid = 17630699 | pmc = 2596720 | doi = 10.1021/bi7006146 }}</ref>

임상적으로는 베타-락타메이스 억제제로만 사용되지만, [[임균]], [[박테로이데스 프라길리스]], [[아시네토박터]] 세균에 자체적인 항균 활성을 보인다.<ref name="PMC4325763">{{저널 인용|제목=Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii|저널=Antimicrobial Agents and Chemotherapy|성=Penwell|이름=William F.|성2=Shapiro|이름2=Adam B.|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325763/|날짜=2015-03|권=59|호=3|쪽=1680–1689|doi=10.1128/AAC.04808-14|issn=0066-4804|pmc=4325763|pmid=25561334|성3=Giacobbe|이름3=Robert A.|성4=Gu|이름4=Rong-Fang|성5=Gao|이름5=Ning|성6=Thresher|이름6=Jason|성7=McLaughlin|이름7=Robert E.|성8=Huband|이름8=Michael D.|성9=DeJonge|이름9=Boudewijn L. M.}}</ref>

<!-- Society and culture -->
특허가 출원된 것은 1977년, 사용이 승인된 것은 1986년이다.<ref name=Fis2006>{{서적 인용| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=492 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA492 |language=en}}</ref>

== 의학적 사용 ==
복합 제제로 [[암피실린/설박탐]],<ref>{{웹 인용| title=Unasyn- ampicillin sodium and sulbactam sodium injection, powder, for solution | work = DailyMed | publisher = U.S. National Library of Medicine | date=29 March 2023 | url= https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12eeb72a-403d-41be-bae4-4cb930862884 | access-date=25 May 2023}}</ref> [[세포페라존/설박탐]] 등이 여러 나라에서 이용 가능하다.<ref>{{웹 인용| url = https://www.drugs.com/international/sulperazon.html | title = Sulperazon | publisher = [[drugs.com]] }}</ref>

또 다른 복합 제제인 [[설박탐/둘로박탐]]은 2023년 5월 미국에서 사용 승인되었다.<ref>{{보도자료 인용| title=FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria | website=U.S. Food and Drug Administration | date=24 May 2023 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria | access-date=24 May 2023}}</ref>

== 작용 기전 ==
설박탐은 베타-락타메이스 억제제로 주로 사용하여, 항균 능력이 강력하지만 베타-락타메이스로 인해 파괴되는 암피실린 같은 베타-락탐 계열 항생제를 보호하는 역할을 한다.<ref>{{저널 인용| vauthors = Crass RL, Pai MP | title = Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors | journal = Pharmacotherapy | volume = 39 | issue = 2 | pages = 182–195 | date = February 2019 | pmid = 30589457 | doi = 10.1002/phar.2210 | s2cid = 58567725 }}</ref> 설박탐 자체도 [[베타-락탐]] 고리가 있으며, [[페니실린 결합 단백질]](PBP) 1, 3을 억제하여 약한 항균 활성을 가진다. PBP-2는 억제하지 않는다.<ref>{{저널 인용| vauthors = Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA | display-authors = 6 | title = Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii | journal = Antimicrobial Agents and Chemotherapy | volume = 59 | issue = 3 | pages = 1680–1689 | date = March 2015 | pmid = 25561334 | pmc = 4325763 | doi = 10.1128/AAC.04808-14 }}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{저널 인용| vauthors = Singh GS | title = Beta-lactams in the new millennium. Part-II: cephems, oxacephems, penams and sulbactam | journal = Mini Reviews in Medicinal Chemistry | volume = 4 | issue = 1 | pages = 93–109 | date = January 2004 | pmid = 14754446 | doi = 10.2174/1389557043487547 }}

[[분류:베타-락타메이스 억제제]]
[[분류:락탐]]
[[분류:설폰]]
[[분류:카복실산]]